Methylsulfonylmethane (MSM)

Does MSM Work for Dogs with Arthritis? The Honest Bottom Line

Methylsulfonylmethane (MSM) is biologically plausible as a joint-support ingredient, but there are no high-quality clinical trials in dogs demonstrating that it reduces osteoarthritis pain or improves mobility on its own. Almost everything known about MSM in osteoarthritis comes from human and laboratory-animal studies rather than from arthritic dogs, so its use in canine joint care is best described as a low-certainty, unproven adjunct rather than an established treatment (Barbeau-Grégoire et al., 2022).

What Is MSM and Why Is It in So Many Joint Products?

MSM, also called dimethyl sulfone, is a small sulfur-containing organic molecule classified as a dietary supplement for both humans and animals. Although it is often marketed as a naturally occurring sulfur compound, commercial MSM is almost always synthetically produced under controlled conditions, typically from dimethyl sulfoxide (DMSO). Sulfur itself is biologically essential, incorporated into amino acids such as methionine and cysteine and involved in collagen and connective-tissue structure, which is the basis for marketing MSM as a sulfur donor for joints, skin, and coat. MSM holds Generally Recognized as Safe (GRAS) status for certain applications, but it is worth being precise that GRAS pertains to safety at typical intakes and says nothing about effectiveness for arthritis.

How Might MSM Work? (Mechanism of Action)

Several mechanisms are proposed, and all of them are inferred in dogs rather than directly demonstrated. The sulfur-donor hypothesis holds that MSM supplies bioavailable sulfur for synthesizing cartilage matrix components such as glycosaminoglycans and for the disulfide bonds in collagen. Laboratory work also suggests MSM may down-regulate pro-inflammatory cytokines such as interleukin-1 beta and tumor necrosis factor-alpha and may inhibit COX-2 expression, and separately that it may reduce oxidative stress by supporting glutathione and scavenging reactive oxygen species. A further hypothesis is that MSM influences pain signaling and membrane fluidity. The essential caveat is that these effects have been observed mainly in cell cultures, rodent models, and human data; in dogs they are plausible but largely hypothetical, and they support the idea that MSM could help rather than evidence that it does.

Why Might It Help an Arthritic Joint, and What Is the Catch? (Biologic Rationale)

The rationale rests on sulfur being a genuine structural element of cartilage and connective tissue, plus the anti-inflammatory and antioxidant signals seen in the lab. The catch is meaningful: there is no strong evidence that otherwise healthy dogs eating complete commercial diets are sulfur-deficient, because quality dog food generally supplies adequate methionine and cysteine. If a dog is not short of sulfur, it is unclear that adding more through MSM provides any structural benefit, which weakens the most intuitive part of the rationale.

What Is Known About Form and Absorption? (Bioavailability)

MSM is rarely sold alone in canine products. It is typically one ingredient among many, combined with glucosamine, chondroitin, green-lipped mussel, omega-3s, collagen, boswellia, or turmeric. This matters scientifically because it makes attribution nearly impossible: when a dog on a multi-ingredient product improves, the contribution of MSM specifically cannot be isolated. Beyond this, dog-specific pharmacokinetic data are limited, and pharmacokinetics may differ substantially from the human data often used to justify use, so how much orally administered MSM reaches canine joint tissue in an active form is not well established.

What Does the Clinical Evidence in Dogs Show?

The direct canine clinical evidence is essentially absent. There are no robust, placebo-controlled trials evaluating MSM alone for naturally occurring osteoarthritis in pet dogs. The most relevant canine and feline synthesis, a 2022 systematic review and meta-analysis, identified the strongest analgesic evidence for omega-3-enriched diets and supplements, moderate evidence for cannabidiol, weak efficacy for collagen, and a very marked non-effect for chondroitin-glucosamine; MSM-containing combinations were not supported by strong, high-quality clinical data in dogs (Barbeau-Grégoire et al., 2022). The attribution problem deepens the uncertainty: because MSM is so often paired with chondroitin and glucosamine, ingredients that this meta-analysis found ineffective for canine pain, any perceived benefit from a combination product is more plausibly explained by other components such as omega-3s, by the caregiver placebo effect, or by concurrent changes like weight loss or natural disease fluctuation.

What Do Human and Laboratory Studies Add? (Translational Support)

The supporting evidence sits one or two species removed from the dog:

Human studies:

• A systematic review found positive but not definitive evidence that MSM outperforms placebo for mild to moderate knee osteoarthritis in better-designed trials; many DMSO studies suffered from poor methodology (Brien et al., 2008)

Rodent studies:

• MSM had no effect on cartilage formation in growing rats over 4 weeks, but produced a dose-dependent decrease in cartilage degeneration in an osteoarthritis-prone mouse strain over 13 weeks (Ezaki et al., 2013)

Dog-adjacent studies:

• A study in healthy military working dogs used a multi-ingredient botanical blend containing MSM and measured inflammatory markers rather than arthritis outcomes; interleukin-6 did not differ significantly between groups, and the design cannot isolate MSM's effect or support arthritis claims (Lee et al., 2018)

Extrapolating from these sources to dogs is limited by species differences in pharmacokinetics, joint biomechanics, and outcome measurement. Using inconclusive human data or small rodent signals to make strong canine claims is not scientifically justified.

What Does the Science Say About Safety and Interactions?

At commonly used oral doses, MSM appears to have a favorable safety profile in dogs, but dog-specific long-term, high-dose data are limited. The rodent literature provides a relevant caution: high-dose MSM was associated with decreased liver and spleen weight and organ atrophy in growing animals, so the margin between a potentially beneficial intake and a potentially harmful one is not clearly defined for dogs (Ezaki et al., 2013). Reported effects at standard intakes are mild, mostly gastrointestinal upset such as soft stool or decreased appetite, and occasionally increased thirst or urination. A practical, science-based concern is inadvertent stacking: because MSM appears in many joint supplements, chews, and food toppers, total intake can climb well beyond studied levels when multiple products are combined. Meaningful drug interactions have not been well characterized in dogs.

Limitations and Future Directions

The central limitation is straightforward: biological plausibility is moderate, but direct canine clinical evidence is very low to absent, and the supporting data come almost entirely from other species or from combination products that prevent attribution. Cautious, hedged language is therefore appropriate when describing MSM, using terms such as may, might, and has not been proven in dogs. The most useful future work would be well-designed, placebo-controlled trials testing MSM as a single agent in dogs with naturally occurring osteoarthritis, using objective outcomes and characterizing both efficacy and the high-dose safety margin. Until such data exist, MSM is most accurately framed as an experimental, low-certainty adjunct rather than a treatment with demonstrated benefit.